Q3 EPS Forecast for Gilead Sciences Increased by Analyst

Gilead Sciences, Inc. (NASDAQ:GILD) – Equities researchers at Leerink Partnrs increased their Q3 2025 earnings per share (EPS) estimates for shares of Gilead Sciences in a report released on Monday, July 14th. Leerink Partnrs analyst D. Graybosch now expects that the biopharmaceutical company will post earnings per share of $2.37 for the quarter, up from their prior forecast of $2.26. The consensus estimate for Gilead Sciences’ current full-year earnings is $7.95 per share. Leerink Partnrs also issued estimates for Gilead Sciences’ Q4 2025 earnings at $1.98 EPS.

Several other equities analysts have also recently issued reports on the stock. JPMorgan Chase & Co. boosted their target price on shares of Gilead Sciences from $120.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday, March 27th. Morgan Stanley raised their target price on Gilead Sciences from $130.00 to $135.00 and gave the company an “overweight” rating in a research report on Friday, April 25th. Cantor Fitzgerald assumed coverage on Gilead Sciences in a research note on Tuesday, April 22nd. They issued an “overweight” rating and a $125.00 price target for the company. Needham & Company LLC reiterated a “hold” rating on shares of Gilead Sciences in a research report on Wednesday, May 21st. Finally, Oppenheimer dropped their price objective on Gilead Sciences from $132.00 to $125.00 and set an “outperform” rating on the stock in a report on Friday, April 25th. Nine investment analysts have rated the stock with a hold rating, fourteen have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, Gilead Sciences presently has an average rating of “Moderate Buy” and a consensus target price of $111.38.

Gilead Sciences Stock Performance

Shares of GILD stock opened at $109.06 on Tuesday. The business has a 50-day simple moving average of $108.15 and a 200-day simple moving average of $104.91. The company has a quick ratio of 1.23, a current ratio of 1.37 and a debt-to-equity ratio of 1.16. The stock has a market cap of $135.66 billion, a PE ratio of 22.96, a price-to-earnings-growth ratio of 0.72 and a beta of 0.29. Gilead Sciences has a 52-week low of $70.33 and a 52-week high of $119.96.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings data on Thursday, April 24th. The biopharmaceutical company reported $1.81 EPS for the quarter, beating the consensus estimate of $1.77 by $0.04. The business had revenue of $6.67 billion during the quarter, compared to analysts’ expectations of $6.77 billion. Gilead Sciences had a net margin of 20.76% and a return on equity of 51.93%. The business’s quarterly revenue was down .3% compared to the same quarter last year. During the same period in the previous year, the business posted ($1.32) EPS.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently modified their holdings of the company. Southland Equity Partners LLC boosted its position in Gilead Sciences by 2.9% in the 2nd quarter. Southland Equity Partners LLC now owns 3,285 shares of the biopharmaceutical company’s stock valued at $364,000 after buying an additional 92 shares during the period. Redwood Financial Network Corp lifted its position in shares of Gilead Sciences by 4.0% during the 4th quarter. Redwood Financial Network Corp now owns 2,530 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 98 shares during the last quarter. Argentarii LLC boosted its position in shares of Gilead Sciences by 3.0% during the 1st quarter. Argentarii LLC now owns 3,392 shares of the biopharmaceutical company’s stock worth $380,000 after acquiring an additional 99 shares in the last quarter. Nicolet Advisory Services LLC increased its stake in Gilead Sciences by 2.9% in the fourth quarter. Nicolet Advisory Services LLC now owns 3,580 shares of the biopharmaceutical company’s stock valued at $322,000 after purchasing an additional 100 shares during the last quarter. Finally, Peak Financial Advisors LLC grew its position in shares of Gilead Sciences by 1.7% in the 1st quarter. Peak Financial Advisors LLC now owns 6,040 shares of the biopharmaceutical company’s stock valued at $677,000 after buying an additional 100 shares during the last quarter. 83.67% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, insider Johanna Mercier sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 16th. The shares were sold at an average price of $110.17, for a total value of $330,510.00. Following the sale, the insider directly owned 120,168 shares of the company’s stock, valued at approximately $13,238,908.56. The trade was a 2.44% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Daniel Patrick O’day sold 10,000 shares of the stock in a transaction that occurred on Monday, June 30th. The stock was sold at an average price of $110.45, for a total transaction of $1,104,500.00. Following the transaction, the chief executive officer directly owned 615,725 shares of the company’s stock, valued at $68,006,826.25. The trade was a 1.60% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 61,000 shares of company stock valued at $6,623,445 over the last 90 days. Company insiders own 0.27% of the company’s stock.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 27th. Investors of record on Friday, June 13th were given a $0.79 dividend. The ex-dividend date of this dividend was Friday, June 13th. This represents a $3.16 annualized dividend and a yield of 2.90%. Gilead Sciences’s payout ratio is 66.53%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.